Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rafael Holdings Inc (NY: RFL )

1.390 -0.050 (-3.47%)
Official Closing Price Updated: 7:00 PM EDT, Aug 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 17,688
Open 1.430
Bid (Size) 1.380 (15)
Ask (Size) 1.600 (2)
Prev. Close 1.440
Today's Range 1.380 - 1.430
52wk Range 1.290 - 2.360
Shares Outstanding 100
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
RFL Stock Earnings: Rafael Holdings Reported Results for Q3 2024
Rafael Holdings just reported results for the third quarter of 2024. 
Via InvestorPlace
Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results
Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive upside potential 
From Rafael Holdings, Inc.
Via GlobeNewswire

Performance

YTD
-24.04%
-24.04%
1 Month
N/A
N/A
3 Month
-13.13%
-13.13%
6 Month
-27.60%
-27.60%
1 Year
-39.57%
-39.57%

More News

Read More
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
From Cyclo Therapeutics, Inc.
Via Business Wire
Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
From Rafael Holdings, Inc.
Via GlobeNewswire
RFL Stock Earnings: Rafael Holdings Reported Results for Q1 2024
Via InvestorPlace
Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results
From Rafael Holdings, Inc.
Via GlobeNewswire
Cyclo Therapeutics Reports Third Quarter 2023 Financial Results
From Cyclo Therapeutics, Inc.
Via Business Wire
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results
From Rafael Holdings, Inc.
Via GlobeNewswire
Cyclo Therapeutics Reports Second Quarter 2023 Financial Results
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.
From Cyclo Therapeutics, Inc.
Via Business Wire
Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update
From Rafael Holdings, Inc.
Via GlobeNewswire
Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)
From Cyclo Therapeutics, Inc.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Rafael Holdings Announces up to $5 Million Share Repurchase Program
From Rafael Holdings, Inc.
Via GlobeNewswire
Rafael Holdings Reports Second Quarter Fiscal 2023 Financial Results
From Rafael Holdings, Inc.
Via GlobeNewswire
Top Real Estate Stocks That May Plunge
Via Benzinga
Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results
From Rafael Holdings, Inc.
Via GlobeNewswire
Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities
From Rafael Holdings, Inc.
Via GlobeNewswire
Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results
From Rafael Holdings, Inc.
Via GlobeNewswire
Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer
From Cornerstone Pharmaceuticals
Via GlobeNewswire
Alibaba, Zoom Video And 76 Biggest Movers From Yesterday
Via Benzinga
Why These Casino Stocks Are Moving Lower, Here's 45 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
More Than $27 Million Bet On Seres Therapeutics? 4 Penny Stocks Insiders are Buying
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.